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This review discusses the known cardiovascular effects of
smoking and the effects of nicotine without tobacco smoke and
interprets the available data on cardiovascular risk during nico-
tine replacement therapy (NRT). Nicotine gum and patches are
now approved for over the counter sale in the United States.
Smokers with cardiovascular disease are advised to seek physi-
cian counseling before using nicotine products, but information
regarding the safety of these products in such patients is not
readily available to most physicians. Nicotine may contribute to
cardiovascular disease, presumably by hemodynamic conse-
quences of sympathetic neural stimulation and systemic catechol-
amine release. However, there are many potential cardiovascular
toxins in cigarette smoke other than nicotine. The doses of
nicotine obtained by regular cigarette smoking generally exceed
those delivered by NRTs, and the cardiovascular effects of nicotine
are, in general, more intense when delivered rapidly by cigarette
smoking than the slower delivery by transdermal nicotine or
nicotine gum. Because the dose–cardiovascular response relation
for nicotine is flat, the effects of cigarette smoking in conjunction
with NRT are similar to those of cigarette smoking alone. Ciga-
rette smoking increases blood coagulability, a major risk factor
for acute cardiovascular events, whereas transdermal nicotine
does not appear to do so. Clinical trials of NRT in patients with
underlying, stable coronary disease suggest that nicotine does not
increase cardiovascular risk. At worst, the risks of NRT are no
more than those of cigarette smoking. The risks of NRT for
smokers, even for those with underlying cardiovascular disease,
are small and are substantially outweighed by the potential
benefits of smoking cessation.
(J Am Coll Cardiol 1997;29:1422–31)
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Nicotine gum and patches are now approved for over the
counter sale in the United States. The package inserts advise
smokers with cardiovascular disease to seek physician counsel-
ing before using the products, but information on the safety of
nicotine in the setting of cardiovascular disease is not readily
available to most physicians.
Cigarette smoking is well known to increase the risk of
cardiovascular disease. Nicotine affects cardiovascular function
and could contribute to cardiovascular disease. Of concern is
whether nicotine medications pose a cardiovascular risk, and, if
so, how does this risk compare to that of cigarette smoking?
The risk–benefit analysis for nicotine medication in patients
with active or silent heart disease is important both in helping
to make decisions on rational therapy for smoking cessation
and for other potential indications for nicotine therapy, such as
ulcerative colitis.
Cigarette smoking accelerates atherosclerosis, producing
premature atherosclerosis at epicardial coronary arteries, the
aorta, the carotid and cerebral arteries and large arteries in the
peripheral circulation (1,2). Smoking is also associated with an
increased risk of acute cardiovascular events, including acute
myocardial infarction, sudden death and stroke. Other effects
include aggravation of stable angina pectoris, intermittent
claudication and vasospastic angina, rethrombosis after throm-
bolysis and restenosis after angioplasty (3–7).
The acute cardiovascular effects of nicotine are of primary
concern with respect to clinically relevant risks of nicotine
replacement therapy (NRT) because of their potentially seri-
ous nature. There have been anecdotal reports of acute
myocardial infarction and stroke in patients taking NRT, with
or without simultaneous cigarette smoking (Table 1). The
possible contribution of nicotine to acute cardiovascular events
is the major focus of this review.
Smoking-related atherosclerosis is not necessarily an effect
of nicotine (1,2). It is important to recognize that cigarette
smoke is a complex mixture of chemicals that includes not only
nicotine but also potentially cardiotoxic substances, such as
carbon monoxide, oxidant gases and polycyclic aromatic hy-
drocarbons. The role of nicotine, if any, in causing acute or
chronic cardiovascular disease has not been definitely demon-
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strated. If nicotine contributes to smoking-related atheroscle-
rosis, it is unlikely to be of clinical importance during the
relatively brief duration of NRT for smoking cessation.
Mechanisms by Which Cigarette Smoking
Contributes to Acute Vascular Events
Mechanisms by which cigarette smoking is likely to contrib-
ute to acute vascular events include 1) induction of a hyper-
coagulable state; 2) increased myocardial work; 3) carbon
monoxide–mediated reduced oxygen-carrying capacity of the
blood; 4) coronary vasoconstriction; and 5) catecholamine
release.
Hypercoagulable state. Several lines of evidence suggest
that cigarette smoking–mediated thrombosis is a major factor
in acute vascular events. Epidemiologic studies (2) indicate
that cigarette smoking increases the risk of acute myocardial
infarction and sudden death much more than it increases the
risk of angina pectoris. The former are believed to be mediated
by thrombosis, the latter primarily by hemodynamic factors.
Recent research with thrombolysis supports this concept. The
prognosis in patients with myocardial infarction after treat-
ment with thrombolysis is better in smokers than in nonsmok-
ers (8). Smokers, at the time of myocardial infarction, were
younger, had fewer cardiac risk factors and had less severe
underlying coronary disease than did nonsmokers. Enhanced
thrombosis superimposed on less severely stenotic arteries best
explains these observations. Observations that smokers who
continue to smoke after thrombolysis or angioplasty have
substantially increased risk of reinfarction or reocclusion sup-
port the idea that thrombosis is a major mechanism of
smoking-related events (5,7).
Increased myocardial work. Although surveys of outpa-
tient blood pressure measurement report that smokers have a
lower blood pressure than matched nonsmokers (9), more
recent studies of ambulatory blood pressure monitoring show
that long-term cigarette smoking increases average heart rate
and blood pressure throughout the day (10,11). In addition,
each cigarette transiently increases heart rate and blood pres-
sure (12). Cigarette smoking causes an acute increase in the
stiffness of large peripheral arteries (13,14). Cigarette smoking
also increases myocardial contractility (15,16). Thus, myocar-
dial work is increased. When myocardial blood flow increases,
coronary blood flow must increase to provide necessary oxygen
and nutrients. Where coronary blood flow is limited, the blood
flow requirements of the heart may not be able to be met,
resulting in ischemia.
Abbreviations and Acronyms
CGRP 5 calcitonin growth-related peptide
ECG 5 electrocardiographic
HDL 5 high density lipoprotein
LDL 5 low density lipoprotein
NO 5 nitric oxide
NRT 5 nicotine replacement therapy
VLDL 5 very low density lipoprotein
Table 1. Summary of Published Adverse Cardiovascular Events in People Using Nicotine Replacement Therapy
Age (yr)/Gender
Underlying Cardiovascular
Disease
Type and Dose of
Nicotine Product Time of Onset of Event
Concurrent
Cigarette
Smoking
AF (109–111)
52/M Coronary disease, Hx and
paroxysmal AF
2-mg gum 5 min after 1st piece of gum, day
3 of use
Unknown
35/M None known 2-mg gum, 30
pieces/day
At night during sleep, after 2-mo
use
Unknown
55/F None known 21-mg patch 5 h after applying patch Yes
MI (112–114)
34/M Normal CAs, except for
thrombosed LAD
21-mg patch Angina began several hours after
1st patch; MI 10 AM, day 14
Yes
47/M Recent MI with 50% LAD
stenosis
21-mg patch While smoking 1st cigarette and
wearing patch, day 7
Yes
39/M Normal coronary angiogram 21-mg patch Several hours after application of
patch, day 20
No
69/F Unknown 44-mg patch Day 25 Unknown
Cerebral isch (114–116)
40/M Internal carotid aneurysm clipped,
persistent cerebral artery spasm
One 10-mg patch 4 h after 1st patch application,
postoperative day 8
Yes
43/F Unknown 44-mg patch Day 3 Unknown
70/F Unknown 22-mg patch Day 11 of 22-mg patch, after
4 wk of 44-mg patch
Unknown
62/F None known 21-mg patch Day 21 Unknown
Numbers in parentheses are reference numbers. AF 5 atrial fibrillation; CAs 5 coronary arteries; F 5 female; Hx 5 hypertension; isch 5 ischemia; LAD 5 left
anterior descending coronary artery; M 5 male; MI 5 myocardial infarction.
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Carbon monoxide effects on oxygen delivery. Smokers in-
hale carbon monoxide in cigarette smoke, and carboxyhemo-
globin levels average ;5%, but may be $10%. This compares
to levels of 0.5% to 2% in nonsmokers, depending on their
exposure to automobile exhaust. Carbon monoxide binds to
hemoglobin, reducing both the amount of hemoglobin avail-
able to carry oxygen and also impeding oxygen release by
hemoglobin that is not directly binding carbon monoxide (17).
In experimental studies, inhalation of carbon monoxide at
levels comparable to those found in cigarette smokers has been
shown (18–20) to reduce exercise tolerance in patients with
angina pectoris, intermittent claudication and chronic obstruc-
tive lung disease. Carbon monoxide exposure in people with
obstructive coronary disease also results in a greater degree of
exercise-induced ventricular dysfunction, as well as an in-
creased number and complexity of ventricular arrhythmias
during exercise (21,22). Carbon monoxide inhalation reduces
the ventricular fibrillation threshold in animals and may con-
tribute to atherogenesis (23,24).
Coronary vasoconstriction. Coronary vasoconstriction re-
duces myocardial blood supply and could produce ischemia or
arrhythmias. Cigarette smoking increases coronary blood flow,
associated with a small decrease in coronary vascular resis-
tance, in people with normal coronary arteries, presumably a
response to increased myocardial work and the need for
additional blood supply (25). However, in people with obstruc-
tive coronary disease, cigarette smoking results in a lesser
increase, no change or even a decrease in coronary blood flow,
depending on the severity of the underlying coronary disease
(25,26). In these patients, cigarette smoking increases coronary
vascular resistance, consistent with coronary vasoconstriction.
Cigarette smoking is associated with increased risk of vaso-
spastic angina and a poor response to medications in patients
who have vasospastic angina (27,28). Cigarette smoking has
been observed to acutely produce vasospasm during angiogra-
phy (6).
Pretreatment with calcium channel blocking agents or
nitroglycerin results in an increase in coronary blood flow after
cigarette smoking in patients with coronary artery disease who
had no increase after cigarette smoking alone, further support-
ing the idea that cigarette smoking normally results in coronary
vasoconstriction (29). Recently, intracoronary Doppler mea-
surements have demonstrated (30) that cigarette smoking
constricts epicardial arteries as well as increases total coronary
vascular resistance. Thus, the impairment of coronary blood
flow by cigarette smoking appears to result from constriction of
both epicardial and resistance blood vessels.
Catecholamine release. Cigarette smoking acutely in-
creases plasma levels of norepinephrine and epinephrine and
increases 24-h urinary excretion of these catecholamines
(31,32). The effects of cigarette smoking on coronary blood
flow appear to be catecholamine mediated because the in-
crease in coronary vascular resistance is blocked by alpha-
adrenoceptor blocking agents (33). In addition to mediating
the hemodynamic effects of cigarette smoking, catecholamines
could contribute to arrhythmogenesis. For example, acute
ischemia combined with smoking-related catecholamine re-
lease could result in a greater risk of sustained and potentially
fatal tachyarrhythmias. Cigarette smoking has been shown (34)
to accelerate atrioventricular node conduction, which could
contribute to supraventricular arrhythmias. Catecholamine
release has been speculated to account for the greater risk of
sudden death in smokers than in nonsmokers (35).
Mechanisms by Which Cigarette Smoking
May Promote Atherosclerosis
Cigarette smoking could accelerate atherosclerosis by a
variety of mechanisms. Some of those more prominently
mentioned include 1) adverse effects on lipids; 2) producing
endothelial damage or dysfunction, or both; 3) hemodynamic
stress; 4) oxidant injury; 5) neutrophil activation; 6) enhanced
thrombosis; and 7) increased fibrinogen and blood viscosity.
Effects of cigarette smoking on lipids. Smokers on average
have a higher risk lipid profile than do nonsmokers. Levels of
very low density lipoprotein (VLDL) are higher; high density
lipoprotein (HDL) cholesterol levels (primarily HDL-2) are
lower; triglycerides are higher; and apoprotein A1 levels are
perhaps lower in smokers than in nonsmokers (36,37). There is
also some evidence (38) that smokers have higher levels of
oxidized low density lipoprotein (LDL), which is believed to
promote atherogenesis. Oxidized LDL is taken up preferen-
tially by macrophages, which become the foam cells that are an
integral part of the atherosclerotic plaque. These abnormali-
ties in the blood lipid profile appear to reverse, at least in part,
within 2 weeks of smoking cessation (39).
Endothelial toxicity. Endothelial damage is thought to be
an initiating event in atherosclerosis. There is evidence that
cigarette smoking produces endothelial damage (40). For
example, endothelial changes have been described in the
umbilical artery of babies of smoking mothers (41). Endothe-
lial changes included swelling, blebbing and contraction, with
resultant opening of endothelial junctions and formation of
subendothelial edema.
Cigarette smoking is associated with impaired flow-
mediated, endothelium-dependent peripheral arterial vasodi-
lation, an effect that is at least partly reversible after smoking
cessation (42). Smokers without atherosclerosis have coronary
vasoconstrictor responses to acetylcholine, which in the pres-
ence of endothelial cell function normally produces vasodila-
tion (43). Impaired arterial vasodilation in smokers appears to
be a consequence of impaired release of endothelium-derived
relaxing factor (believed to be nitric oxide [NO]) (44,45).
Normal NO release has potentially beneficial cardiovascular
effects in mediating acetylcholine-induced coronary vasodila-
tion and inhibiting platelet aggregation, smooth muscle cell
proliferation and adhesion of monocytes to the endothelium.
Impaired release of NO in cigarette smokers could contribute
to acute cardiovascular events and to accelerated atherogene-
sis.
Hemodynamic stress may contribute to endothelial dam-
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age, as occurs in chronic hypertension. As discussed, regular
smoking increases daytime blood pressure, blood pressure
variability and heart rate. Persistent heart rate elevation has
been shown (46) in primates on an atherogenic diet to
accelerate atherosclerosis. Thus, hemodynamic effects of ciga-
rette smoking would be expected to result in more turbulent
blood flow and could contribute to endothelial damage.
Oxidant injury. Cigarette smoke contains many oxidant
gases. Reduced plasma levels of the antioxidant glutathione
and increased levels of lipid peroxidation products have been
measured in the plasma of smokers, reflecting the oxidant
stress of cigarette smoke (47,48). As noted previously, cigarette
smoking is believed to be associated with oxidation of LDL,
which may promote atherosclerosis (38). Oxidant substances in
cigarette smoke appear to be responsible for endothelial
dysfunction. Antioxidants such as vitamin C reverse the im-
pairment in endothelium-mediated vasodilation in smokers
(49).
Neutrophil activation. Cigarette smoking is consistently
associated with increased circulating neutrophil counts (50).
Neutrophil counts decline rapidly after cessation of cigarette
smoking (51). An elevated neutrophil count is a risk factor for
coronary events (52). Neutrophils may contribute to ischemic
heart disease through release of oxygen-derived free radicals,
proteases and leukotrienes (53). These mediators can result in
endothelial cell injury and aggregation and activation of plate-
lets, which in turn can aggravate coronary ischemia.
Enhanced thrombosis. Cigarette smoking produces a hy-
percoagulable state, associated with platelet activation and
possibly other changes in clotting factors (54). Enhanced
viscosity is contributed to by increased fibrinogen levels and
increased red cell mass in cigarette smokers (55). Hypercoagu-
lability may contribute to atherosclerosis, presumably by re-
lease of platelet factors that promote smooth muscle cell
migration and other effects that promote atherosclerosis (56).
Fibrinogen and blood viscosity. Increased fibrinogen is one
of the strongest predictors of coronary events (57). Cigarette
smoking increases fibrinogen levels, although the mechanism is
unclear. Smokers also have elevated red blood cell mass, as a
response to long-term carbon monoxide exposure (58). Carbon
monoxide reduces oxygen-carrying capacity, resulting in a state
of relative hypoxemia. In response, red blood cell masses
increase, allowing more oxygen to be carried to body organs.
Both increased fibrinogen and increased red blood cell mass
increase blood viscosity, which is believed to contribute to
platelet activation, which, as discussed, promotes atherogene-
sis. Fibrinogen may also contribute to atherosclerosis through
direct activation of platelets, acting on specific platelet recep-
tors (57).
Cardiovascular Pharmacology of Nicotine
Thus far, the discussion has focused on the cardiovascular
effects of cigarette smoking. At this point, the focus will be the
known effects of nicotine itself.
Nicotine binds to nicotinic cholinergic receptors, which are
located in the brain, autonomic ganglia, the adrenals and
neuromuscular junction (59). The main cardiovascular effect of
nicotine is sympathetic neural stimulation. Sympathomimetic
effects are mediated by several mechanisms. Central nervous
system–mediated sympathetic stimulation can occur through
activation of peripheral chemoreceptors, direct effects on the
brain stem and effects on more caudal portions of the spinal
cord. Intrapulmonary chemoreceptors may also contribute to
brain-mediated sympathetic arousal. The site that appears to
be most sensitive to low levels of nicotine is the carotid
chemoreceptor. Peripheral mechanisms include catecholamine
release from the adrenals and direct release or enhancement of
release of catecholamines from vascular nerve endings.
Nicotine works primarily by enhancing the release of vari-
ous neurotransmitters, including epinephrine, norepinephrine,
dopamine, acetylcholine, serotonin, vasopressin, glutamate,
NO (60), calcitonin growth-related peptide (CGRP) (60) and
beta-endorphin. Thus, in addition to catecholamine-mediated
actions, some other of these effects, such as acetylcholine,
serotonin, NO, CGRP or vasopressin release, may contribute
to effects of nicotine on blood vessels.
Salient observations on the pharmacokinetics and pharma-
codynamics of nicotine most relevant to cardiovascular safety
are summarized in Table 2. More detail is available in com-
prehensive reviews of the pharmacology of nicotine (59,61).
Acute Cardiovascular Effects of Nicotine
Hemodynamic actions of nicotine. The hemodynamic ef-
fects of cigarette smoking appear to be mediated by nicotine.
Intravenous nicotine, nicotine nasal spray and nicotine chew-
ing gum all acutely increase heart rate up to 10 to 15 beats/min
and increase blood pressure up to 5 to 10 mm Hg, responses
similar to the effects of cigarette smoking (62–64). Transder-
mal nicotine appears to cause lesser acute hemodynamic
changes than smoking (32).
Nicotine increases cardiac output by increasing both heart
rate and myocardial contractility. Nicotine gum chewing has
been shown to aggravate regional myocardial hypoperfusion in
patients with known coronary artery disease (65). Nicotine
constricts some vascular beds, such as the skin. Cutaneous
vasoconstriction explains the reduction in fingertip skin tem-
perature that is seen with administration of nicotine (63).
There is evidence that cutaneous vasoconstriction is modu-
lated at least in part by release of vasopressin because the
effect was inhibited by administration of a vasopressin antag-
onist (66). Nicotine appears to dilate other vascular beds, such
as skeletal muscle (67,68). Skeletal muscle vasodilation may in
part be a result of the increase in cardiac output, although
animal studies suggest that release of epinephrine from nerve
terminals may also contribute (13).
In anesthetized dogs, coronary blood flow has a biphasic
response to nicotine. Initially, blood flow increases, in the large
coronary vessels as well as in the smaller resistance vessels,
believed to be a result of increased myocardial metabolic
demand. Secondarily, there is a decrease in blood flow that
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appears to be mediated by alpha-adrenergic vasoconstriction
of coronary resistance vessels (69,70). As described previously,
cigarette smoking may constrict coronary arteries, presumed
due to nicotine-mediated catecholamine release. Of note, the
chewing of 4 mg of nicotine gum by healthy nonsmokers has
also been shown (70) to blunt the increase in coronary blood
flow that occurs with an increase in heart rate, produced either
by nicotine or cardiac pacing. This finding confirms that
nicotine is capable of constricting coronary arteries even at low
doses in humans.
Nicotine has been shown (71) to worsen myocardial dys-
function in regionally “stunned,” ischemic myocardium of
anesthetized dogs. In a placebo-controlled experiment, tran-
sient ischemia was induced in dogs by 15 min of left anterior
descending coronary artery clamping. Segmental shortening
recovered to only 29% of the preischemic baseline in nicotine-
pretreated animals (80 mg/kg body weight intravenously over
15 min) compared with 54% for saline-treated control dogs
(p , 0.01). The dose of nicotine did not alter heart rate, blood
pressure or blood flow or cause myocyte necrosis.
Nicotine and platelet function. There has been consider-
able research into the effects of nicotine on platelet function.
Nicotine appears not to have a significant direct effect on
platelets in vitro, at least at concentrations relevant to human
smoking (72). Studies of long-term nicotine administration in
rodents do not show increased platelet activity; rather, they
show reduced platelet aggregability (73). However, in a study
in dogs with partially occluded coronary arteries (74), intrave-
nous nicotine increased the frequency and severity of phasic
reductions in blood flow, an effect that indicates platelet
aggregation. The effects of nicotine on phasic blood flow were
blocked by phentolamine, an alpha-adrenergic blocker, consis-
tent with the idea that catecholamine release mediates the
effects. Unfortunately, the study is not readily generalizable to
human smoking because the dogs were naive (nontolerant) to
nicotine, and the dose (80 mg/kg over 3 to 5 min) was large
(equivalent to a human smoking approximately five cigarettes
in 5 min).
Platelet studies in human smokers yield conflicting results
and are difficult to interpret because cigarette smoke contains
many other factors besides nicotine that could promote plate-
let aggregation. Studies of nicotine gum and transdermal
nicotine do not show evidence of platelet activation (32,75).
Also of potential importance in assessing the role of
nicotine in platelet activation are studies of urinary thrombox-
ane A2 metabolite excretion in tobacco snuff users (76).
Thromboxane A2 is released from platelets when they aggre-
gate, and excretion of thromboxane A2 metabolites reflects in
vivo platelet activation. Snuff users have long-term exposure to
levels of nicotine comparable to those experienced by cigarette
smokers but are not exposed to tobacco combustion products.
Snuff users had no evidence of platelet activation. Thrombox-
ane A2 metabolite excretion rates in snuff users were similar to
those who did not use tobacco and lower than those of
cigarette smokers (who are known to have activated platelets),
suggesting that nicotine itself is not responsible for platelet
activation.
Nicotine and prostaglandins. Nicotine can inhibit the in
vitro synthesis of prostacyclin in isolated blood vessels and
isolated hearts (77,78). Prostacyclin is thought to be important
in vascular homeostasis in that it is a local vasodilator and has
antiplatelet aggregation effects. It has been speculated that
nicotine could produce an imbalance between the vasodilating
antiplatelet prostacyclin and the vasoconstricting platelet-
aggregating thromboxane A2, the latter of which is released
from platelets. One early study (79) in smokers using radioim-
munoassay of urinary eicosanoid metabolites supported the
idea that nicotine might inhibit prostacyclin synthesis. How-
ever, more recent studies (80–82) using gas chromatographic–
mass spectrometric specific assays for urinary prostacyclin
metabolites have found no evidence that cigarette smoking is
associated with reduced release of prostacyclin. In contrast,
Table 2. Pharmacokinetic and Pharmacodynamic Considerations Concerning Cardiovascular Safety of Nicotine
Nicotine from cigarette smoke is absorbed rapidly and results in arterial plasma concentrations in body organs 6–10 times higher than venous plasma
concentrations (117). Slower delivery systems, such as nicotine gum or patch, will produce much lower peak arterial concentrations
When smokers involved in most treatment trials are considered, the level of nicotine produced and the daily dose of nicotine delivered by standard doses of NRT
are less than that typically taken in from cigarette smoking (118–122)
When people using NRT to quit smoking continue to smoke, the resulting plasma nicotine concentrations are not likely to be much greater than those observed
before attempting to quit. Only modest increases in plasma nicotine concentration are observed when transdermal nicotine is combined with usual smoking
(108)
Because of rapid delivery of high concentrations of nicotine, with minimal time for development of tolerance, cigarette smoking results in more intense acute
cardiovascular effects than the same dose of nicotine absorbed from NRT (123)
Cigarette smoking and transdermal nicotine appear to have similar overall hemodynamic effects; however, cigarette smoking activates coagulation and increases
24-h epinephrine excretion, whereas transdermal nicotine does not (32)
The cardiovascular dose–response relation for nicotine is relatively flat; that is, after a threshold effect, nicotine produces little more effect despite higher blood
levels (106)
Combining cigarette smoking with nicotine administered by other routes appears to have cardiovascular effects similar to cigarette smoking alone (107); thus,
smoking while using nicotine-reduced therapy would not be expected to have additional effects but would produce the same effects as smoking alone
Numbers in parentheses are reference numbers. NRT 5 nicotine replacement therapy.
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prostacyclin metabolite excretion increased, suggesting stimu-
lation of endothelial activity. Smokeless tobacco users, who
have high systemic levels of nicotine, do not have increased
prostacyclin metabolite excretion compared with people who
use no tobacco. Thus, there is no convincing evidence that
nicotine affects prostacyclin synthesis or release in people.
Chronic Cardiovascular Effects of Nicotine
Long-term atherosclerosis experiments. An increased rate
of development of aortic (83) and carotid (84) atherosclerosis
during nicotine treatment of cholesterol-fed rabbits has been
observed. Although these two studies suggest that nicotine may
be atherogenic in the presence of hypercholesterolemia, the
rabbit atherosclerosis models used are not readily generaliz-
able to humans: 1) The plasma concentrations of cholesterol
produced were severalfold greater than those usually seen in
hypercholesterolemic humans, and there may be a threshold
below which a synergistic effect of nicotine and hypercholes-
terolemia is no longer clinically relevant. 2) High per-kilogram
doses of nicotine were used in one study (11 mg/kg per day)
(84), and plasma concentrations were not measured in either
study. Another study (85) used a lower dose of nicotine
(1 mg/kg per day) and a 2% cholesterol diet and failed to
demonstrate increased atherosclerosis.
Nicotine and endothelial cell injury. Nicotine at concen-
trations similar to those of cigarette smokers modulates the
structural and functional characteristics of cultured vascular
smooth muscle and endothelial cells (86,87). Animal studies
(88–90) support the idea that nicotine can produce endothelial
cell injury, although the mechanism is not clear. Oral nicotine
administered to rats to achieve blood levels comparable to
those in human smokers produced greater myointimal thick-
ening of the aorta after experimental injury (denudation of the
endothelium with a balloon catheter) than that in control
animals (91). The excessive myointimal thickening in nicotine-
treated animals is consistent with a response to persistent
injury to endothelial cells. In support of the relevance of
animal or in vitro studies to the effects of nicotine in humans,
Davis et al. (92) reported an increase in the number of
endothelial cells found in venous blood (reflecting endothelial
injury) and a decrease in platelet aggregate ratios (reflecting
platelet aggregation) in nonsmokers who smoked tobacco but
not nontobacco cigarettes.
Nicotine and lipids. Nicotine, by release of catechol-
amines, induces lipolysis and releases plasma free fatty acids.
There is evidence that these free fatty acids are primarily taken
up by the liver, which might be expected to increase the
synthesis of VLDL, consistent with changes described in
cigarette smokers (93).
Results of studies of the effects of nicotine on lipids in
animals are conflicting. Injection of nicotine or feeding of
nicotine has been reported (83,84,88) to increase total choles-
terol in rabbits and monkeys receiving a high cholesterol diet.
Nicotine feeding in squirrel monkeys for 2 years has been
shown (94) to increase plasma levels of LDL. The mechanism
in monkeys included both accelerated synthesis of LDL
through lipolysis of HDL and VLDL and impaired clearance
of LDL. Of importance in interpreting these animal studies is
that high doses of nicotine have been administered, often by an
oral route, and without measurement of blood levels of
nicotine to determine exposure adequately.
Most studies in humans given nicotine preparations suggest
that nicotine delivered in these forms does not have an adverse
effect on lipid profiles. In one study (95), nicotine chewing gum
(2 mg eight times a day) was given to healthy nonsmokers for
2 weeks. No changes in plasma concentrations of triglycerides;
total, HDL or LDL cholesterol; or apolipoprotein A1 or B
were noted. In another study (96), 20 nonsmokers with ulcer-
ative colitis received transdermal nicotine (15 mg/day) for 12
weeks. No changes in plasma lipids were found. Also, there
were no changes in white cell count or platelet activation
(assessed by platelet volume and expression of P-selectin), and
no evidence of endothelial damage (assessed by plasma Von
Willebrand factor antigen levels) was detected. Data from
smokers who stop smoking and use transdermal nicotine
indicate that lipids change toward normal while taking nicotine
(97).
Nicotine Replacement in Patients With
Cardiovascular Disease
In this section, evidence from cardiovascular adverse event
reports and from clinical trials of NRT is examined.
Case reports of adverse cardiovascular events. In view of
the known adverse effects of cigarette smoking and the current
understanding of the pharmacology of nicotine, as reviewed
previously, it is to be expected that acute cardiovascular events
occurring in people using nicotine medications would raise
concern. Accordingly, there are scattered published reports
linking nicotine replacement therapies to acute cardiovascular
events. Acute myocardial infarction in five patients who were
smoking cigarettes while using nicotine patches has been
reported in the press (98). Full details of these cases have not
been published, but they were carefully reviewed by a Food
and Drug Administration (FDA) advisory committee and
judged not to be causally related to nicotine (99). Published
case reports of adverse cardiovascular events are summarized
in Table 1. Postmarketing surveillance data (New Drug Appli-
cation Supplement) have shown only isolated and sporadic
cardiovascular events, with no consistent relationship to the
NRT.*
Establishing whether the relation between NRT and car-
diovascular events is causal is difficult. Acute cardiovascular
events are common in cigarette smokers, and the increased risk
for such events persists beyond the time when they stop
smoking. Therefore, it is impossible to ascertain from retro-
*Marion Merrell Dow (Hoechst Marion Roussel), NDA 18-612, NDA
20-066, Summary of Safety Information, Vol. 1, 19–48, August 20, 1993; Alza
Corporation NDA 20-165, Integrated Summary of Safety Data, Vols. 11.51–
11.55, August 7, 1995.
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spective reports whether acute cardiovascular events reflect
the risk of underlying disease, cigarette smoking, concurrent
cigarette smoking or nicotine medications, alone or in combi-
nation. Smokers and ex-smokers are at increased risk for acute
myocardial infarction, and a higher than average number of
infarctions would be expected in the general population of
people trying to quit smoking, with or without the use of NRT
to aid smoking cessation.
Because of the relative infrequency of the cardiovascular
events of concern, the number of subjects in a formal study
needs to be quite large. One large source of observational data
is the Lung Health Study cohort, in which 5,887 middle-aged
smokers with chronic obstructive pulmonary disease were
followed up for 5 years. During that study (100), two-thirds of
the subjects were provided with smoking cessation therapy,
including nicotine gum. Many of these subjects used nicotine
gum heavily for several years. A comparison of smokers versus
quitters with nicotine gum versus quitters without nicotine gum
showed no increase in hospital admissions for cardiovascular
events with nicotine gum treatment (101). In fact, the opposite
was observed. Study participants who quit smoking and used
nicotine gum had a lower hospital admission rate for cardio-
vascular disease than participants who quit smoking and did
not use gum. Hospital admission rates were similar among
subjects who failed to quit smoking, with or without nicotine
gum use. In considering these results, it should be remembered
that nicotine treatment was not randomly assigned, and there-
fore the usual caveats regarding sources of bias from compar-
isons of subgroups must be applied. For example, some
participants motivated to use nicotine gum may have had a
lower cardiovascular risk to begin with. Nevertheless, the data
strongly suggest that nicotine gum use did not increase the rate
of hospital admissions for cardiovascular disease.
Clinical trials of NRT in patients with cardiovascular
disease. The results of two controlled trials of NRT in patients
with cardiovascular disease have been published (102,103).
The first study was a 5-week, placebo-controlled trial of 14 to
21 mg/day of transdermal nicotine in 156 patients with stable
coronary artery disease (102). Cardiac symptoms were re-
corded, and in a subgroup, 24-h ambulatory electrocardio-
graphic (ECG) monitoring was performed before and during
the first and last weeks of treatment. Of note, the quit rates
were low, so there was much concomitant smoking and patch
use in each group. Frequency of angina declined both in
nicotine and placebo groups, with no difference between
treatments. Ambulatory ECG monitoring revealed no differ-
ences in arrhythmias or ST segment depression changes in
nicotine- versus placebo-treated patients. Plasma nicotine con-
centrations averaged 14.1 ng/ml with transdermal nicotine in
those who did and 21.1 ng/ml in those who did not quit
smoking. Joseph et al. (103) recently reported the results of a
large Veterans Affairs cooperative study of 584 smokers with
cardiovascular disease. Patients received a 10-week course of
transdermal nicotine (beginning at 21 mg/day and tapering to
7 mg/day) or placebo. Many participants continued to smoke
cigarettes. The incidence of primary end points (death, myo-
cardial infarction, cardiac arrest and admission to the hospital
for increased severity of angina, arrhythmias or congestive
heart failure) was similar in both groups (nicotine group: 5.4%;
placebo group: 7.9%). These two studies (102,103) found no
evidence of aggravation of coronary artery disease by NRT.
A recent experimental study (104) further supports the
safety of transdermal nicotine, even in the setting of concom-
itant cigarette smoking, in patients with severe coronary artery
disease. Thirty-six male smokers with a baseline $5% revers-
ible perfusion defect by quantitative thallium-201 single-
photon emission computed tomography were treated with 14-
and 21-mg nicotine patches sequentially. Despite instructions
to stop, most continued smoking, although they smoked fewer
cigarettes per day. In the setting of increasing plasma nicotine
levels (average: 15.8 ng/ml at baseline, 24.2 ng/ml for 14-mg
nicotine patches, 30.4 ng/ml for 21-mg nicotine patches), there
was a highly significant reduction in total exercise-induced
perfusion defect size (average: 17.5% at baseline, 12.6% for
14-mg nicotine patches, 11.8% for 21-mg nicotine patches). No
patient had a significant increase in myocardial ischemia while
using nicotine patches. The progressive reduction in defect size
was most closely related to the reduction in the blood carboxy-
hemoglobin concentration, which had decreased as a conse-
quence of smoking fewer cigarettes. This study (104) suggests
that carbon monoxide or some other component of tobacco
smoke rather than nicotine is most important in limiting
myocardial nutrient supply in patients with coronary heart
disease. In that the perfusion defect size is known to have
predictive implications for future myocardial infarction or
death, or both (105), this study (104) suggests that treatment
with transdermal nicotine is not hazardous in patients with
coronary heart disease and may even reduce cardiovascular
risk in continuing smokers if the smoking rate is reduced.
Risk Versus Benefit Considerations:
Cigarette Smoking Versus NRT
In summary, cigarette smoking appears to precipitate acute
cardiac events by at least three mechanisms. One mechanism,
and perhaps the most important, is by producing a hyperco-
agulable state and promoting thrombosis. Studies with high
doses of nicotine in animals suggest that this effect could be
due to significantly increased levels of circulating epinephrine
released by bolus dose nicotine. Importantly, such effects do
not appear to be present during NRT with transdermal nico-
tine or nicotine gum. A second mechanism is the delivery of
carbon monoxide, which limits oxygen delivery to the heart.
This is a problem with cigarette smoking but not NRT. A third
mechanism is through hemodynamic effects of nicotine. These
include an increase in heart rate and blood pressure, which in
turn increase myocardial work and oxygen demand, as well as
constriction of coronary arteries, which would impair blood
flow and oxygen supply to the heart.
The data presented in this review indicate that nicotine
delivered by nicotine polacrilex gum or transdermal nicotine
1428 BENOWITZ ET AL. JACC Vol. 29, No. 7
CARDIOVASCULAR TOXICITY OF NICOTINE June 1997:1422–31
has similar or lesser effects than cigarette smoking with respect
to increasing myocardial work. No data are available on the
effects of transdermal nicotine on coronary blood flow. How-
ever, because the vasoconstricting effects of nicotine appear to
be mediated by sympathetic nervous system activation, and we
have found that transdermal nicotine produces less sympa-
thetic activation than does cigarette smoking, it is likely that
transdermal nicotine would have no greater, and probably less,
an effect than cigarette smoking on coronary vascular resis-
tance.
The risk of smoking while using nicotine replacement
products appears not to be greater than the risk of smoking
alone. The explanation presumably lies in the flat dose–
response relation for nicotine (106,107) and the fact that even
when people smoke ad libitum during NRT, the total intake of
nicotine is no more than modestly increased compared with
that during usual smoking (108). Because smoking is usually
substantially reduced during NRT compared with that before
quitting, it is likely that the risk of cardiovascular events will be
less, even with concurrent smoking, because it is smoking that
carries with it the greatest burden of cardiovascular risk.
The risks of NRT in patients with cardiovascular disease
have not been fully elucidated, but available data on patients
with cardiovascular disease as well as experimental studies of
the pharmacokinetics and pharmacodynamics of nicotine in
healthy smokers, suggest that the risk is not great. In contrast,
cigarette smoking remains the greatest cause of morbidity and
mortality from cardiovascular disease in middle-aged people.
NRT has been shown to substantially increase the likelihood of
smoking cessation. The available information suggests that the
benefit of NRT to aid smoking cessation in patients with
coronary heart disease who cannot stop smoking without such
therapy outweighs the risks of continued smoking or of NRT
itself.
We thank Donna Causey, MD, Jane Gorsline, PhD, Charles Gorodetsky, MD,
William Byrd, PharmD and Craig Pratt, MD for their comments and Kaye Welch
for editorial assistance.
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